“… 10 Interestingly, exposure to BP in the AFF population was smaller when compared with 3 other large US and European population-based studies in which 90.5%, 78%, and 69% of AFF patients had evidence of previous BP or Dmab use and a smaller UK study where 70% of AFF patients were previously exposed to BP. 16 , 17 , 22 , 24 However, 3 smaller studies in South Korea and Thailand found a smaller proportion of AFF patients, ranging from 35.3% to 44.4%, with previous exposure to BPs. 14 , 18 , 25 This could be explained by different populations having different baseline risks for AFF, with more at-risk populations having AFFs with less exposure to BP.…”